Bladder tumor markers: From hematuria to molecular diagnostics - Where do we stand?

Expert Review of Anticancer Therapy

Volumn 8, Issue 7, 2008, Pages 1111-1123

  Shirodkar, Samir P ^a   Lokeshwar, Vinata B ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Bladder cancer; Diagnosis; Surveillance; Tumor marker

Indexed keywords

CYTOKERATIN; FAS ANTIGEN; GELATINASE A; GELATINASE B; HYALURONIC ACID; HYALURONIDASE; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; MEMBRANE ANTIGEN; MESSENGER RNA; NUCLEAR MATRIX PROTEIN 22; PROTEIN BCLA4; SURVIVIN; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ANXIETY; BLADDER CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER PAIN; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HUMAN; MICROSATELLITE MARKER; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SYMPTOM; UNITED STATES; BLADDER TUMOR; CYSTOSCOPY; DIAGNOSTIC PROCEDURE; GENETICS; METHODOLOGY; PATHOLOGY; URINE;

ANTIGENS, NEOPLASM; CYSTOSCOPY; HEMATURIA; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 48849089432     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.7.1111     Document Type: Review

References (136)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology and End Results (SEER) Program. Oncologist 12, 20-37 (2007).
2. Prout GR Jr, Wesley MN, McCarron PG et al. Survival experience of black patients and white patients with bladder carcinoma. Cancer 100(3), 621-630 (2004).
3. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J. Clin. Oncol. 24(35), 5519-5527 (2006).
4. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J. Urol. 177(2), 437-443 (2007).
5. Hendricksen K, Witjes J. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr. Opin. Urol. 17(5), 352-357 (2007).
6. Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. Sci. World J. 6, 2617-2625 (2006).
7. von der Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Semin. Oncol. 29, 3-14 (2002).
8. Grossfeld GD, Wolf JS Jr, Litwan MS et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am. Fam. Physician 63(6), 1145-1154 (2001).
9. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18), 1315-1330 (2003).
10. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J. Natl Cancer Inst. 95(8), 588-597 (2003).
11. Liou IS. Urothelial cancer biomarkers for detection and surveillance. Urology 67, 25-33 (2006).
12. Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66, 35-63 (2005).
13. Lokeshwar VB, Selzer MG. Urinary bladder tumor markers. Urol. Oncol. 24, 528-537 (2006).
14. Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J. Urol. 177, 1277-1282 (2007).
15. Vriesema JL, Povcki MH, Kiemeney LA, Witjes JA. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: utility analysis. Urology 56, 793-797 (2000).
16. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 10, 311-322 (2002).
17. Yuri EJ, Meng MV, Carroll PR. Evaluation of the patient with hematuria. Med. Clin. North Am. 88, 329-343 (2004).
18. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol. Clin. North Am. 25(4), 661-676 (1998).
19. Messing EM, Madeb R, Young T et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107, 2173-2179 (2006).
20. Zein TA, Milad MF. Urine cytology in bladder tumors. Int. Surg. 76, 52-54 (1991).
21. Gil-Salom M, Sánchez MC, Chuan P, Clar F, Santamaría J, García-Sisamón F. Multiple mucosal biopsies and postoperative urinary cytology in patients with bladder cancer. Eur. Urol. 17, 281-285 (1990).
22. Badalament RA. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60, 1423-1427 (1987).
23. Konchuba AM, Schellhammer PF, Alexander JP, Wright GL Jr. Flow cytometric study comparing paired bladder washing and voided urine for bladder cancer detection. Urology 33, 89-96 (1989).
24. Brown FM. Urine cytology. It is still the gold standard for screening? Urol. Clin. North Am. 27, 25-37 (2000).
25. Kinders R, Jones T, Root R et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin. Cancer Res. 4, 2511-2520 (1998).
26. Package insert. BTA-Stat Test.
27. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA star test. J. Urol. 161, 443-446 (1999).
28. Boman H, Hedelin H, Holmäng S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J. Urol. 167, 80-83 (2002).
29. Leyh H, Marberger M, Conort P et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur. Urol. 35, 52-56 (1999).
30. Giannopoulos A, Manousakas T. Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J. Urol. 166, 470-475 (2001).
31. Gutiérrez Baños JL, Rebollo Rodrigo MH, Antolín Juárez FM, Martín García B. NMP 22, BTA star test and cytology in the diagnosis of bladder cancer: a comparative study. Urol. Int. 66, 185-190 (2001).
32. Wald M, Halachmi S, Amiel G et al. Bladder tumor antigen stat test in non-urothelial malignant urologic conditions. Isr. Med. Assoc. J. 4, 174-175 (2002).
33. Raitanen MP, Kaasinen E, Lukkarinen O et al; Finnbladder Group. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer. Urology 57, 680-684 (2001).
34. Raitanen MP; The FinnBladder Group. The role of BTA Star Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J. Urol. 26, 45-50 (2008).
35. Carpinito GA, Stadler WM, Briggman JV et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol. 156, 1280-1285 (1996).
36. Tsui KH, Chen SM, Wang TM et al. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J. Androl. 9, 711-715 (2007).
37. Lee MY, Tsou MH, Cheng MH, Chang DS, Yang AL, Ko JS. Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma. World J. Urol. 18, 401-405 (2000).
38. Gutiérrez Baños JL, Rebollo Rodrigo MH, Antolín Juárez FM, Martín García B. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol. Int. 66, 185-190 (2001).
39. Shariat SF, Marberger MJ, Lotan Y et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J. Urol. 176, 919-926 (2006).
40. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA star. J. Urol. 162, 53-57 (1999).
41. Miyanaga N, Akaza H, Tsukamoto S et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int. J. Clin. Oncol. 8, 369-373 (2003).
42. Serretta V, Lo Presti D, Visile P, Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 52, 793-796 (1998).
43. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol. 159, 394-398 (1998).
44. Package insert. NMP22® Test Kit.
45. Moonen PM, Kiemeney LA, Witjes JA. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur. Urol. 48, 951-956 (2005).
46. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295, 299-305 (2006).
47. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7), 810-816 (2005).
48. Lokeshwar VB, Cerwinka WH, Lokeshwar BL. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res. 65, 2243-2250 (2005).
49. Lokeshwar VB, Young MJ, Goudarzi G et al. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res. 59, 4464-4470 (1999).
50. Lokeshwar VB, Schroeder GL, Selzer MG et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95, 61-72 (2002).
51. Hautmann S, Toma M, Lorenzo Gomez MF et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur. Urol. 46, 466-471 (2004).
52. Lokeshwar VB, Obek C, Pham HT et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J. Urol. 163, 348-356 (2000).
53. Schroeder GL, Lorenzo-Gomez MF, Hautmann SH, Friedrich MG, Ekici S, Huland H, Lokeshwar V. A side by side comparison of cytology and biomarkers for bladder cancer detection. J. Urol. 172, 1123-1126 (2004).
54. Sun Y, He DL, Ma Q et al. Comparison of seven screening methods in the diagnosis of bladder cancer. Chin. Med. J. (Engl.) 119, 1763-1771 (2006).
55. Lokeshwar VB, Block NL. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol. Clin. North Am. 27, 53-61 (2000).
56. Eissa S, Kassim SK, Labib RA et al. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 103(7), 1356-1362 (2005).
57. Chiou SK, Jones MK, Tarnawski AS. Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med. Sci. Monit. 9, 25-29 (2003).
58. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett. 249, 49-60 (2007).
59. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J. Urol. 26, 59-65 (2008).
60. Wu Y, Wang G, Wei J, Wen X. Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. Ind. J. Med. Sci. 59, 235-242 (2005).
61. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285, 324-328 (2001).
62. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J. Cancer Res. Clin. Oncol. 134(6), 659-665 (2008).
63. Kenney DM, Geschwindt RD, Kary MR, Linic JM, Sardesai NY, Li ZQ. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol. 28, 57-62 (2007).
64. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression and mortality. Cancer 109, 1106-1113 (2007).
65. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int. J. Cancer 116(1), 100-104 (2005).
66. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70, 482-486 (2007).
67. Helmy H, Seddek MN, Basta MT et al. Cytokeratin shedding in urine as a biological marker for bladder cancer: monoclonal antibody-based evaluation. Br. J. Urol. 68, 248-253 (1991).
68. Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, Le Guillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J. Urol. 158, 338-341 (1997).
69. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94, 2914-2922 (2002).
70. Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 55, 223-226 (2000).
71. Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 56, 228-231 (2000).
72. May M, Hakenberg OW, Gunia S et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 70, 449-453 (2007).
73. Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder. Ann. Clin. Lab. Sci. 36, 31-38 (2006).
74. Hakenberg OW, Fuessel S, Richter K et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64, 1121-1126 (2004).
75. Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I. Cytokeratin 20, a new marker for early detection of bladder cell carcinoma? J. Urol. 160, 1971-1974 (1998).
76. Retz M, Lehmann J, Amann E, Wullich B, Röder C, Stöckle M. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J. Urol. 169, 86-89 (2003).
77. Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH. Functional characterization of the bladder cancer marker, BLCA-4. Clin. Cancer Res. 10, 1384-1391 (2004).
78. Konety BR, Nguyen TS, Brenes G et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol. 164, 634-639 (2000).
79. Konety BR, Nguyen TS, Dhir R et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin. Cancer Res. 6, 2618-2625 (2000).
80. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology 66, 1256-1260 (2005).
81. Svatek RS, Herman MP, Lotan Y et al. Soluble Fas - a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106, 1701-1707 (2006).
82. Maas S, Warskulat U, Steinhoff C et al. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology 63, 392-397 (2004).
83. Perabo FG, Mattes RH, Wirger A et al. Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo. Urol. Oncol. 6, 163-169 (2001).
84. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur. Urol. 52(5), 1388-1396 (2007).
85. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82, 1359-1366 (1998).
86. Sier CF, Casetta G, Verheijen JH et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res. 6, 2333-2340 (2000).
87. Vasala K, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 62(5), 952-957 (2003).
88. Di Carlo A, Terracciano D, Mariano A, Macchia V. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol. Rep. 15(5), 1321-1326 (2006).
89. Henderson ER, Larson DD. Telomeres - what's new at the end? Curr. Opin. Genet. Dev. 1, 538-543 (1991).
90. Rhyu MS. Telomers, telomerase and immortality. J. Natl Cancer Inst. 87, 884-894 (1995).
91. Shay JW, Wright WE, Werbin H. Loss of telomeric DNA during aging may predispose cells to cancer. Int. J. Oncol. 3, 559-563 (1993).
92. Eissa S, Swellam M, Ali-Labib R, Mansour A, El-Malt O, Tash FM. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. J. Urol. 178, 1068-1072 (2007).
93. Sanchini MA, Gunelli R, Nanni O et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294, 2052-2056 (2005).
94. Kinoshita H, Ogawa O, Kakehi Y et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J. Natl Cancer Inst. 89, 724-730 (1997).
95. Bian W, Xu Z. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma. Int. J. Urol. 14, 108-111 (2007).
96. Bravaccini S, Sanchini MA, Granato AM et al. Urine telomerase activity for the detection of bladder cancer in females. J. Urol. 178, 57-61 (2007).
97. Weikert S, Krause H, Wolff I et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive-detection of bladder cancer. Int. J. Cancer 117, 274-280 (2005).
98. Counter CM, Gupta J, Harley CB, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85, 2315-2320 (1995).
99. Yokogi H, Wada Y, Moriyama-Gonda N, Igawa M, Ishibe T. Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization. Br. J. Urol. 78, 699-703 (1996).
100. Skacel M, Liou LS, Pettay JD, Tubbs RR. Interphase fluorescence in-situ hybridization in the diagnosis of bladder cancer. Front. Biosci. 7, e27-e32 (2002).
101. Yoder BJ, Skacel M, Hedgepeth R et al. Reflex Uro Vision testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am. J. Clin. Pathol. 127, 295-301 (2007).
102. Laudadio J, Keane TE, Reeves HM et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 96, 1280-1285 (2005).
103. Riesz P, Lotz G, Páska C et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol. Oncol. Res. 13, 187-194 (2007).
104. Bergman J, Reznichek RC, Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int. 101, 26-29 (2008).
105. Marín-Aguilera M, Mengual L, Ribal MJ et al. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet. Cytogenet. 173, 131-135 (2007).
106. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 168, 1950-1954 (2002).
107. Krause FS, Rauch A, Schrott KM, Engehausen DG. Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays? World J. Urol. 24, 418-422 (2006).
108. Karran P. Microsatellite instability and DNA mismatch repair in human cancer. Semin. Cancer Biol. 7, 15-24 (1996).
109. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int. J. Cancer 94, 67-72 (2001).
110. Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G, Piazzini M. Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J. Urol. 175, 2032-2037 (2006).
111. Szarvas T, Kovalszky I, Bedi K et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol. Rep. 18, 405-409 (2007).
112. Frigerio S, Padberg BC, Strebel RT et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int. J. Cancer 121, 329-338 (2007).
113. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat. Med. 3, 621-624 (1997).
114. Amira N, Mourah S, Rozet F et al. Noninvasive molecular detection of bladder cancer recurrence. Int. J. Cancer 101, 293-297 (2002).
115. Shigyo M, Sugano K, Tobisu K, Tsukamoto T, Sekiya T, Kakizoe T. Molecular followup of newly diagnosed bladder cancer using urine samples. J. Urol. 166, 1280-1285 (2001).
116. Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt. Can. J. Urol. 4, 400-405 (1997).
117. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. ImmunoCyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 161, 1486-1489 (1999).
118. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58, 367-371 (2001).
119. Toma MI, Friedrich MG, Hautmann SH et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J. Urol. 22, 145-1479 (2004).
120. Têtu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod. Pathol. 18, 83-89 (2005).
121. Schmitz-Dräger BJ, Tirsar LA, Schmitz-Dräger C et al. Immunocytology in the assessment of patients with asymptomatic hematuria. World J. Urol. 26, 31-37 (2008).
122. Pianton E, Daniel L, Verriele V et al. Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab. Invest. 83(6), 845-852 (2003).
123. Lodde M, Mian C, Negri G et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology 61, 243-247 (2003).
124. Dalbagni G, Presti J, Reuter V. Genetic alterations in bladder cancer. Lancet 342, 469-471 (1993).
125. Cordon-Cardo C, Reuter VE. Alterations of tumor suppressor genes in bladder cancer. Semin. Diagn. Pathol. 14, 123-132 (1997).
126. Sánchez-Carbayo M, Cordon-Cardó C. Molecular alterations associated with bladder cancer progression. Semin. Oncol. 34, 75-84 (2007).
127. Lu M, Wikman F, Orntoft TF. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin. Cancer Res. 8, 171-179 (2002).
128. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J. Urol. 25, 563-571 (2007).
129. Le Frère-Belda MA, Gil Diez de Medina S, Daher A et al. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium arid bladder carcinomas, according to pRb and p53 protein status. Hum. Pathol. 35(7), 817-824 (2004).
130. George B, Datar RH, Wu L et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J. Clin. Oncol. 25(34), 5352-5358 (2007).
131. Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 6, 678-686 (2005).
132. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J. Urol. 177, 80-83 (2007).
133. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 99, 281-285 (2007).
134. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J. Urol. 177, 481-487 (2007).
135. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr. Opin. Urol. 18, 1-8 (2008).
136. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int. 98, 1090-1093 (2006).